Progression of premature thelarche to central precocious puberty

Pasquino, Anna Maria; Pucarelli, Ida; Passeri, F.; Segni, Maria; Mancini, Maria Antonietta; Municchi, Giovanna

doi:10.1016/s0022-3476(95)70492-2

Cited by 110 publications

(71 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The natural history of progression from premature thelarche (defined by bone age advancement within 2 S.D. of normal, normal growth rate and FSH-predominant responsiveness to acute GnRH stimulation) to CPP was investigated in 100 girls, with a mean age of 5.1 years (15). Their follow-up indicated a 14% progression rate.…”

Section: Cpp and Overlaps With Thelarche Variantsmentioning

confidence: 99%

The use of GnRH agonists in precocious puberty

Mul¹,

Hughes

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

In this review several aspects of gonadotrophin releasing hormone agonists (GnRHa) treatment in central precocious puberty (CPP) are highlighed. These include issues of the definition of precocity, assessment of CPP and thelarche variants. Indications for treatment with GnRH agonists are discussed, not only in CPP but also in children with other reasons to suppress central activation, e.g. adopted or developmental retardation. Finally, outcome data are summarized, both on growth and psychosocial parameters.European Journal of Endocrinology 159 S3-S8

show abstract

Section: Cpp and Overlaps With Thelarche Variantsmentioning

confidence: 99%

The use of GnRH agonists in precocious puberty

Mul¹,

Hughes

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Premature thelarche is considered as a variant of normal development and not evaluated to be pathological (2,3). In individuals with premature thelarche, the growth rate is normal in contrast to CPP, the bone age is not advanced and the basal gonadotropin and estradiol values are at prepubertal levels (4). The cause of premature thelarche is not known exactly and its prevalence is 4.7%.…”

Section: Introductionmentioning

confidence: 99%

“…The cause of premature thelarche is not known exactly and its prevalence is 4.7%. Thirteen % of the cases of premature thelarche may progress to CPP (2,4). The clinical findings, bone age and basal and stimulated gonodotropin levels should be evaluated carefully.…”

Section: Introductionmentioning

confidence: 99%

Clinical and laboratory findings in the differential diagnosis of central precocious puberty and premature thelarche

et al. 2015

View full text Add to dashboard Cite

Aim: In this study, it was aimed to evaluate the clinical, antropometric and laboratory findings of female patients diagnosed with central precocious puberty and to determine the laboratory value with the best diagnostic accuracy in the diagnosis of central precocious puberty. Material and Methods: Female patients whose breast development began before the age of 8 years were included in the study. The data of the patients were obtained by retrospectively examining file records. The chronogical age, age at the time of onset of the complaint, antropometric variables, bone age and hormonal tests were recorded. The patients whose bone age/chronological age ratio was >1 and in whom pubertal response was obtained to gonodotropin releasing hormone stimulation test were considered central precocious puberty and the patients who did not meet these criteria were considered premature thelarche. Receiver operating charecteristic curve (ROC) analysis was performed to determine the diagnostic accuracy of the laboratory variables. Results: Fifty one patients with idiopathic central precocious puberty and 36 patients with premature thelarche were included in the study. In the patients with central precocious puberty, the height standard deviation score, bone age and bone age/chronological age ratio were found to be significantly higher compared to the patients with premature thelarche. The basal luteinizing hormone, basal follicle stimulating hormone, basal luteinizing hormone/follicle stimulating hormone, peak luteinizing hormone, peak follicle stimulating hormone and peak luteinizing hormone/follicle stimulating hormone values were found to be significantly higher in the patients with central precocious puberty. When the cut-off value for the peak luteinizing hormone/follicle stimulating hormone ratio was taken as >0.24, the sensitivity was found to be 100% and specificity was found to be 84%. When the cut-off value for the basal follicle stimulating hormone was taken as >1.9 IU/L, the sensitivity was found to be 71% and specificity was found to be 68%. When the cut-off value for the basal luteinizing hormone was taken as >0.1 IU/L, the sensitivity was found to be 71% and specificity was found to be 64%. Conclusions: In female children, a peak luteinizing hormone/follicle stimulating hormone ratio of >0.24 can be used in the diagnosis of central precocious puberty. However, the findings should be assessed in association with the clinical and antropometric variables. (Türk Ped Arş 2015; 50: 20-6)

show abstract

“…Изредка прежде временное телархе может раз-виться в результате ускоренного созревания ГГя-оси. Также ПТ может быть признаком стремительного развития преждевременно-го полового созревания, что встречается при-мерно в 14 % случаев [104]. Патофизиологию ПТ еще предстоит выяснить.…”

Section: содержание кисспептина у девочек с преждевременным телархеunclassified

Role of Kisspeptine in Regulation of Reproductive Function

et al. 2016

View full text Add to dashboard Cite

Research objective: to identify a role of kisspeptine in the regulation of reproduction function.Materials: literature data by foreign authors for the period from 1985 till 2016.Methods: systematic analysis and compilation of information in the literature.Results. The article provides a review of literature data on research of kisspeptine gene and its receptor; it includes description of their role in regulation of reproduction function and mutation in the genes responsible for realization of kisspeptine and neurokinin signaling pathways. Features of kisspeptine secretion in patients with hypogonadotropic hypogonadism, premature sexual development, hyperprolactinemic deficiency of ovaries, polycystic ovarian syndrome, genital endometriosis and opportunity of kisspeptine use in clinical practice as an ovulation trigger are described.Conclusion. It is necessary to carry out further studies for clarification of kisspeptine role in patients with various diseases and the opportunity of its use as a therapeutic target.

show abstract

Progression of premature thelarche to central precocious puberty

Cited by 110 publications

References 16 publications

The use of GnRH agonists in precocious puberty

The use of GnRH agonists in precocious puberty

Clinical and laboratory findings in the differential diagnosis of central precocious puberty and premature thelarche

Role of Kisspeptine in Regulation of Reproductive Function

Contact Info

Product

Resources

About